Citations

Clear

2286 citation(s) found for "Yu, Anthony".

Sorting nexin 1 loss results in increased oxidative stress and hypertension
Yang, Jian , Asico, Laureano D. , Beitelshees, Amber L. , Feranil, Jun, Wang, Xiaoyan , Jones, John E., Armando, Inés , Cuevas, Santiago , Schwartz, Gary L. , Gums, John G. , Chapman, Arlene B. , Boerwinkle, Eric , Johnson, Julie A. , Felder, Robin A. , Weinman, Edward J., Zeng, Chunyu , José, Pedro A. , Villar, Van Anthony M., Beitelshees, Amber L. , Turner, Stephen T. , Chapman, Arlene B. , Cooper‐DeHoff, Rhonda M.

Mayo Clinic

The FASEB Journal | April 15, 2020 | Volume: 34 | Issue: 6 | Pages: 7941-7957

10.1096/fj.201902448r | PMID 32293069 Get It

Abstract Acute renal depletion of sorting nexin 1 (SNX1) in mice results in blunted natriuretic response and hypertension due to impaired dopamine D 5 receptor (D 5 R) activity. We elucidated the molecular mechanisms for these phenotypes in Snx1 −/− mice. These mice had increased renal expressions of angiotensin II type 1 receptor (AT 1 R), NADPH oxidase (NOX) subunits, D 5 R, and NaCl cotransporter. Basal reactive oxygen species (ROS), NOX activity, and blood pressure (BP) were also higher in Snx1 ‐/‐ mice, which were normalized by apocynin, a drug that prevents NOX assembly. Renal proximal tubule (RPT) cells from hypertensive (HT) Euro‐American males had deficient SNX1 activity, impaired D 5 R endocytosis, and increased ROS compared with cells from normotensive (NT) Euro‐American males. siRNA‐mediated depletion of SNX1 in RPT cells from NT subjects led to a blunting of D 5 R agonist‐induced increase in cAMP production and decrease in Na + transport, effects that were normalized by over‐expression of SNX1. Among HT African‐Americans, three of the 12 single nucleotide polymorphisms interrogated for the SNX1 gene were associated with a decrease in systolic BP in response to hydrochlorothiazide (HCTZ). The results illustrate a new paradigm for the development of hypertension and imply that the trafficking protein SNX1 may be a crucial determinant for hypertension and response to antihypertensive therapy.
Key Components of ICU Recovery Programs: What Did Patients Report Provided Benefit?
McPeake, Joanne , Hibbert, Elizabeth , Bakhru, Rita N. , Bastin, Anthony J. , Butcher, Brad W. , Eaton, Tammy L. , Harris, Wendy, Hope, Aluko A. , Jackson, James C. , Johnson, Annie, Kloos, Janet A. , Korzick, Karen , MacTavish, Pamela , Meyer, Joel , Montgomery-Yates, Ashley , Quasim, Tara , Slack, Andrew, Wade, Dorothy , Still, Mary, Netzer, Giora, Hopkins, Ramona O., Iwashyna, Theodore J. , Sevin, Carla M. , Boehm, Leanne M. , Mikkelsen, Mark E. , Haines, Kimberley

Mayo Clinic

Critical Care Explorations | April 10, 2020 | Volume: 2 | Issue: 4 | Pages: e0088

10.1097/cce.0000000000000088 | PMID 32426730 Get It

Objectives: To understand from the perspective of patients who did, and did not attend ICU recovery programs, what were the most important components of successful programs and how should they be organized. Design: International, qualitative study. Setting: Fourteen hospitals in the United States, United Kingdom, and Australia. Patients: We conducted 66 semi-structured interviews with a diverse group of patients, 52 of whom had used an ICU recovery program and 14 whom had not. Interventions: None. Measurements and Main Results: Using content analysis, prevalent themes were documented to understand what improved their outcomes. Contrasting quotes from patients who had not received certain aspects of care were used to identify perceived differential effectiveness. Successful ICU recovery programs had five key components: 1) Continuity of care; 2) Improving symptom status; 3) Normalization and expectation management; 4) Internal and external validation of progress; and 5) Reducing feelings of guilt and helplessness. The delivery of care which achieved these goals was facilitated by early involvement (even before hospital discharge), direct involvement of ICU staff, and a focus on integration across traditional disease, symptom, and social welfare needs. Conclusions: In this multicenter study, conducted across three continents, patients identified specific and reproducible modes of benefit derived from ICU recovery programs, which could be the target of future intervention refinement.
The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites
Mato, Anthony R. , Nabhan, Chadi , Lamanna, Nicole , Kay, Neil E. , Grinblatt, David L. , Flowers, Christopher R. , Swern, Arlene S., Sullivan, Kristen , Flick, E. Dawn, Ussery, Sarah M. Gressett, Gharibo, Mecide, Kiselev, Pavel , Sharman, Jeff P. , Kay, Neil E , Farber, Charles Michael , Davids, Matthew S.

Mayo Clinic

Blood Advances | April 9, 2020 | Volume: 4 | Issue: 7 | Pages: 1407-1418

10.1182/bloodadvances.2019001145 | PMID 32271900 Get It

Abstract Optimal treatment of chronic lymphocytic leukemia (CLL) remains unclear. The Connect CLL Registry, a United States–based multicenter prospective observational cohort study, enrolled 1494 patients between 2010 and 2014 from predominantly community-based settings. Patients were grouped by line of therapy (LOT) at enrollment. With a median follow-up of 46.6 months (range, 0-63.0 months), median overall survival (OS) was not reached in LOT1, 63.0 months (95% confidence interval [CI], 46.0-63.0 months) in LOT2, and 38.0 months (95% CI, 33.0-47.0 months) in LOT≥3. Bendamustine and rituximab (BR; 33.5%); fludarabine, cyclophosphamide, and rituximab (FCR; 21.4%); and rituximab monotherapy (18.5%) were the most common regimens across LOTs. Median event-free survival (EFS) was similar in patients treated with BR (59.0 months) and FCR (55.0 months) in LOT1; median OS was not reached. In multivariable analysis, BR or FCR vs other treatments in LOT1 was associated with improved EFS (hazard ratio [HR], 0.60; P < .0001) and OS (0.67; P = .0162). Using the Kaplan-Meier product limit, ibrutinib vs other treatments improved OS in LOT2 (HR, 0.279; P = .009), LOT3 (0.441; P = .011), and LOT≥4 (0.578; P = .043). Prognostic modeling of death at 2 years postenrollment identified 3 risk groups: low (mortality rate, 6.2%), medium (14.5%), and high (27.4%). The most frequent adverse events across LOTs were pneumonia (11.6%) and febrile neutropenia (6.2%). These data suggest that advantages of LOT1 FCR over BR seen in clinical trials may not translate to community practice, whereas receiving novel LOT2 agents improved outcomes. This trial was registered at www.clinicaltrials.gov as NCT01081015.
Radiotherapy and Radiosurgery for Treatment of Residual or Recurrent Endolymphatic Sac Tumor Following Previous Microsurgical Resection
Totten, Douglas J. , Manzoor, Nauman F. , Sherry, Alexander D. , Khattab, Mohamed H. , Link, Michael J. , Cmelak, Anthony J. , Haynes, David S. , Carlson, Matthew L. , Attia, Albert, Sherry, Alexander D , Rivas, Alejandro

Mayo Clinic

Otology & Neurotology | April 9, 2020 | Volume: 41 | Issue: 6 | Pages: e759-e762

10.1097/mao.0000000000002639 | PMID 32271262 Get It

Objective: To report and discuss the effectiveness of stereotactic radiosurgery (SRS) or fractionated radiotherapy (FRT) for tumor control following surgical resection of endolymphatic sac tumors (ELST). Study Design: Retrospective case series. Setting: Multi-institutional academic referral centers. Patients: Patients undergoing surgical resection for ELST followed by SRS or FRT. Intervention(s): Surgical resection followed by radiotherapy. Main Outcome Measures: Local tumor control. Results: Two of the five patients experienced tumor recurrence after gross total microsurgical at 78 and 11 months, respectively. The former patient received salvage 3D conformal radiotherapy (3D-CRT) and while the latter patient underwent three courses of salvage SRS for recurrence, two of which were in-field and was disease-free at last follow up. Two additional patients underwent subtotal tumor resection (STR) followed by intensity-modulated radiation therapy (IMRT) and are currently without disease. One patient underwent STR followed by proton-beam therapy (PBT) and was free of disease at most recent follow-up. Conclusion: SRS/FRT remains a useful adjuvant for treatment of residual or recurrent ELSTs, where the risk of revision microsurgical resection is high.
Congenital myasthenic syndrome–associated agrin variants affect clustering of acetylcholine receptors in a domain-specific manner
Shen, Xin‐Ming , Selcen, Duygu , Nazim, Mohammad , Bril, Vera , Tarnopolsky, Mark A. , Brady, Lauren , Fukami, Sae, Amato, Anthony A. , Yiş, Uluç , Engel, Andrew G. , Shen, XinMing, Tarnopolsky, Mark , Ohkawara, Bisei , Ohno, Kinji

Mayo Clinic

JCI Insight | April 8, 2020 | Volume: 5 | Issue: 7 | Pages: No page available

10.1172/jci.insight.132023 | PMID 32271162 Get It

Congenital myasthenic syndromes (CMS) are caused by mutations in molecules expressed at the neuromuscular junction. We report clinical, structural, ultrastructural, and electrophysiologic features of 4 CMS patients with 6 heteroallelic variants in AGRN , encoding agrin. One was a 7.9-kb deletion involving the N-terminal laminin–binding domain. Another, c.4744G>A — at the last nucleotide of exon 26 — caused skipping of exon 26. Four missense mutations (p.S1180L, p.R1509W, p.G1675S, and p.Y1877D) expressed in conditioned media decreased AChR clusters in C2C12 myotubes. The agrin-enhanced phosphorylation of MuSK was markedly attenuated by p.Y1877D in the LG3 domain and moderately attenuated by p.R1509W in the LG1 domain but not by the other 2 mutations. The p.S1180L mutation in the SEA domain facilitated degradation of secreted agrin. The p.G1675S mutation in the LG2 domain attenuated anchoring of agrin to the sarcolemma by compromising its binding to heparin. Anchoring of agrin with p.R1509W in the LG1 domain was similarly attenuated. Mutations of agrin affect AChR clustering by enhancing agrin degradation or by suppressing MuSK phosphorylation and/or by compromising anchoring of agrin to the sarcolemma of the neuromuscular junction.
Accelerated osteocyte senescence and skeletal fragility in mice with type 2 diabetes
Eckhardt, Brittany, Rowsey, Jennifer L. , Thicke, Brianne S, Fraser, Daniel G., O’Grady, Katherine , Bondar, Olga P., Hines, Jolaine M., Thoreson, Andrew R. , Rakshit, Kuntol, Lagnado, Anthony B. , Passos, João F. , Matveyenko, Aleksey V. , Farr, Joshua N. , Passos, João F , Singh, Ravinder , Vella, Adrian , Khosla, Sundeep , Monroe, David G.

Mayo Clinic

JCI Insight | April 8, 2020 | Volume: 5 | Issue: 9 | Pages: No page available

10.1172/jci.insight.135236 | PMID 32267250 Get It

The worldwide prevalence of type 2 diabetes (T2D) is increasing. Despite normal to higher bone density, patients with T2D paradoxically have elevated fracture risk resulting, in part, from poor bone quality. Advanced glycation endproducts (AGEs) and inflammation as a consequence of enhanced receptor for AGE (RAGE) signaling are hypothesized culprits, although the exact mechanisms underlying skeletal dysfunction in T2D are unclear. Lack of inducible models that permit environmental (in obesity) and temporal (after skeletal maturity) control of T2D onset has hampered progress. Here, we show in C57BL/6 mice that a onetime pharmacological intervention (streptozotocin, STZ) initiated in adulthood combined with high-fat diet–induced (HFD-induced) obesity caused hallmark features of human adult-onset T2D, including prolonged hyperglycemia, insulin resistance, and pancreatic β cell dysfunction, but not complete destruction. In addition, HFD/STZ (i.e., T2D) resulted in several changes in bone quality that closely mirror those observed in humans, including compromised bone microarchitecture, reduced biomechanical strength, impaired bone material properties, altered bone turnover, and elevated levels of the AGE CML in bone and blood. Furthermore, T2D led to the premature accumulation of senescent osteocytes with a unique proinflammatory signature. These findings highlight the RAGE pathway and senescent cells as potential targets to treat diabetic skeletal fragility.
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, William J. , Anderson, Benjamin O. , Abraham, Jame , Aft, Rebecca , Allison, Kimberly H. , Blair, Sarah L. , Burstein, Harold J. , Dang, Chau T. , Goldstein, Lori J. , Isakoff, Steven J. , Lyons, Janice A., Matro, Jennifer M. , Moran, Meena S. , Patel, Sameer A. , Pierce, Lori J. , Sitapati, Amy M. , Smith, Mary Lou , Stringer-Reasor, Erica , Telli, Melinda L. , Burns, Jennifer L. , Agnese, Doreen Marie , Elias, Anthony , Giordano, Sharon H. , Goetz, Matthew P. , Krishnamurthy, Jairam , Marcom, Paul Kelly , Mayer, Ingrid A. , Mortimer, Joanne , O'Regan, Ruth M , Rugo, Hope S. , Smith, Karen L. , Soliman, Hatem Hussein , Ward, John Headley , Young, Jessica S. , Kumar, Rashmi , Telli, Melinda L

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 7, 2020 | Volume: 18 | Issue: 4 | Pages: 452-478

10.6004/jnccn.2020.0016 | PMID 32259783 Get It

Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to improvements in survival. In addition to patient and clinical factors, the treatment selection primarily depends on the tumor biology (hormone-receptor status and HER2-status). The NCCN Guidelines specific to the workup and treatment of patients with recurrent/stage IV breast cancer are discussed in this article.
Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline
Pierce, Lori J. , Dietz, Jill R. , Dragun, Anthony , Gelpí, Judith Balmaña, Hofstatter, Erin , Jatoi, Ismail , Kennedy, Elaine, Mayr, Nina A. , Qamar, Rubina , Trombetta, Mark , Harvey, Brittany , Somerfield, Mark R. , Zakalik, Dana , Tung, Nadine , Boughey, Judy C. , Robson, Mark E. , Bedrosian, Isabelle , Isaacs, Claudine , Litton, Jennifer K. , Harvey, Brittany E

Mayo Clinic

Journal of Clinical Oncology | April 3, 2020 | Volume: 38 | Issue: 18 | Pages: 2080-2106

10.1200/jco.20.00299 | PMID 32243226 Get It

PURPOSE To develop recommendations for management of patients with breast cancer (BC) with germline mutations in BC susceptibility genes. METHODS The American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology convened an Expert Panel to develop recommendations based on a systematic review of the literature and a formal consensus process. RESULTS Fifty-eight articles met eligibility criteria and formed the evidentiary basis for the local therapy recommendations; six randomized controlled trials of systemic therapy met eligibility criteria. RECOMMENDATIONS Patients with newly diagnosed BC and BRCA1/ 2 mutations may be considered for breast-conserving therapy (BCT), with local control of the index cancer similar to that of noncarriers. The significant risk of a contralateral BC (CBC), especially in young women, and the higher risk of new cancers in the ipsilateral breast warrant discussion of bilateral mastectomy. Patients with mutations in moderate-risk genes should be offered BCT. For women with mutations in BRCA1/ 2 or moderate-penetrance genes who are eligible for mastectomy, nipple-sparing mastectomy is a reasonable approach. There is no evidence of increased toxicity or CBC events from radiation exposure in BRCA1/ 2 carriers. Radiation therapy should not be withheld in ATM carriers. For patients with germline TP53 mutations, mastectomy is advised; radiation therapy is contraindicated except in those with significant risk of locoregional recurrence. Platinum agents are recommended versus taxanes to treat advanced BC in BRCA carriers. In the adjuvant/neoadjuvant setting, data do not support the routine addition of platinum to anthracycline- and taxane-based chemotherapy. Poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and talazoparib) are preferable to nonplatinum single-agent chemotherapy for treatment of advanced BC in BRCA1/ 2 carriers. Data are insufficient to recommend PARP inhibitor use in the early setting or in moderate-penetrance carriers. Additional information available at www.asco.org/breast-cancer-guidelines .
The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Instititial Lung Diseases: Subgroup with Autoimmune Diseases*
Matteson, Eric L. , Distler, JHW, Seibold, JR, Mittoo, Shikha, Goeldner, R.-G., Schlenker‐Herceg, Rozsa, Quaresma, Manuel , Flaherty, KR, Bonella, Francesco , Kelly, Clive Anthony , Distler, JHW, Hoffmann‐Vold, Anna‐Maria , Distler, Oliver , Stowasser, Susanne

Mayo Clinic

Pneumologie | March 31, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0039-3403189 Get It

At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial
Ganzel, Chezi , Wang, Xin V., Rowe, Jacob M. , Richards, Susan , Buck, Georgina , Marks, David I. , Litzow, Mark R. , Paietta, Elisabeth , Foroni, Letizia, Luger, Selina M. , Wiernik, Peter H. , Douer, Dan , Tallman, Martin S. , Goldstone, Anthony H., Richards, Susan M., Willman, Cheryl L. , Mullighan, Charles G. , Roberts, Kathryn G. , Lazarus, Hillard M.

Mayo Clinic

British Journal of Haematology | March 27, 2020 | Volume: 191 | Issue: 1 | Pages: 37-43

10.1111/bjh.16616 | PMID 32220069 Get It

Summary Late relapse [>3 years from complete remission (CR)] in acute lymphoblastic leukaemia (ALL), is unusual. Data from the MRC UKALLXII/ECOG E2993 trial are presented to evaluate the incidence and characteristics of late relapse in adult ALL. Of 1,909 patients, 1,752 (92%) achieved CR and among these 757 (43·2%) relapsed; 691 (91·3%) within three years and 66 (8·7%) beyond. Among these 66 patients, median time to relapse was 47 (37–144) months. Relapse beyond three years occurred in 3·8% of all who achieved CR. The cumulative risk of relapse was 40%, 43% and 45% at three, five and ten years respectively. Out of the 1 752 patients who achieved CR, 11·7% underwent autologous and 40·6% allogeneic transplant, while in CR1. Of the autologous patients, 43·2% relapsed early and 3·4% relapsed late. However, among the allogeneic patients, 13·2% relapsed early and only 1·3% late. The five‐year overall survival from relapse was 5·8% and 20% in the early and late relapse patients respectively. In conclusion, late relapse in adults with ALL is not uncommon, and is associated with better outcome after relapse compared to early relapse.